Literature DB >> 10954872

Agony and ecstasy: a review of MDMA effects and toxicity.

C Burgess1, A O'Donohoe, M Gill.   

Abstract

BACKGROUND: Ecstasy is a recreational drug with an anecdotal reputation for safety. However, reports of adverse effects and fatalities have increased in the medical and popular press.
METHOD: Literature search and review.
RESULTS: Acute Ecstasy toxicity does not appear to be due to overdose and cannot be solely attributed to the nature of the usual ambient environment. Adverse effects include hyperthermia, seizures, cardiac arrhythmias, hepatotoxicity, hyponatraemia and many psychiatric disorders. Ecstasy causes serotonergic neurotoxicity in the brains of animals at doses close to those used by humans, but its long-term effect on the human brain is unknown.
CONCLUSION: Ecstasy toxicity should be considered in the differential diagnosis of a variety of medical and psychiatric conditions. Given its popularity, both the acute and the potential long-term effects are a cause for concern.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954872     DOI: 10.1016/s0924-9338(00)00396-5

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  10 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  "Ecstasy" induced immunosuppression and herpes zoster ophthalmicus.

Authors:  O M Zwick; D H Fischer; J C Flanagan
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 3.  Synthetic cathinones ("bath salts").

Authors:  Matthew L Banks; Travis J Worst; Daniel E Rusyniak; Jon E Sprague
Journal:  J Emerg Med       Date:  2014-02-22       Impact factor: 1.484

4.  Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy').

Authors:  Natacha Vanattou-Saïfoudine; Ruth McNamara; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2010-05-02       Impact factor: 4.530

Review 5.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 6.  Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators.

Authors:  N Vanattou-Saïfoudine; R McNamara; A Harkin
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

7.  Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Katherine M Keyes; Silvia S Martins; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2008-06-03       Impact factor: 4.492

8.  Ecstasy-induced recurrent toxic hepatitis in a young adult.

Authors:  Ozlem Guneysel; Ozge Ecmel Onur; Haldun Akoglu; Arzu Denizbasi
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

9.  Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men.

Authors:  Cecilia L Moore; Heather F Gidding; Fengyi Jin; Limin Mao; Kathy Petoumenos; Iryna B Zablotska; I Mary Poynten; Garrett Prestage; Matthew G Law; Andrew E Grulich; Janaki Amin
Journal:  AIDS Behav       Date:  2016-10

10.  Reduction of Methylphenidate Induced Anxiety, Depression and Cognition Impairment by Various doses of Venlafaxine in Rat.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Andia Ebrahimzadeh; Setare Farokhi Larijani; Zohreh Khajehamedi
Journal:  Int J Prev Med       Date:  2015-06-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.